Clinical experience from BPaL operational research in Asia, Africa and EEC

Tuesday, November 8, 5:00am - 6:20am (EST)

Time shown in-04:00 America, New York

TB Alliance’s Nix-TB and ZeNix trials have shown that the three-drug, all-oral, 6-month BPaL regimen (bedaquiline, pretomanid and linezolid) can significantly improve success rates for highly drug-resistant TB while simplifying treatment. Following WHO guidelines to implement BPaL under operational research conditions in June 2020, at least 12 countries across Africa, Asia and Europe have commenced operational research or similar programmes. Participants of the symposium will learn about preliminary clinical experience of efficacy, safety and management of adverse events in these countries and discuss how clinical trial findings translate into field experience.

Please see the online program for additional details: https://unionconf2022.abstractserver.com/planner/#/preview/session/6bd9b56ec726bf2c1

Add to Calendar 2022/11/08 11:00:00 2022/11/08 12:20:00 Europe/Paris Clinical experience from BPaL operational research in Asia, Africa and EEC TB Alliance’s Nix-TB and ZeNix trials have shown that the three-drug, all-oral, 6-month BPaL regimen (bedaquiline, pretomanid and linezolid) can significantly improve success rates for highly drug-resistant TB while simplifying treatment. Following WHO guidelines to implement BPaL under operational research conditions in June 2020, at least 12 countries across Africa, Asia and Europe have commenced operational research or similar programmes. Participants of the symposium will learn about preliminary clinical experience of efficacy, safety and management of adverse events in these countries and discuss how clinical trial findings translate into field experience.

Please see the online program for additional details: https://unionconf2022.abstractserver.com/planner/#/preview/session/6bd9b56ec726bf2c1 false MM/DD/YYYY 30 OPAQUE ambQfBYOGzRZxDTimmgh72967

Link: